All In Biotech

Drug Trial Radar · NCT03917381

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

429

Actual

Start

May 14, 2019

Primary completion

Apr 1, 2025

Study completion Aug 3, 2026

Sponsor

Lead sponsor
GenmabIndustry
Sponsor type
Industry
First posted
Apr 17, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this trial is to learn about the antibody acasunlimab (an antibody also known as GEN1046) when it is used alone and when it is used together with standard of care treatment (docetaxel) or another antibody cancer drug, pembrolizumab (with or without chemotherapy), for treatment of patients with certain types of cancer. All subjects will receive active drug; no one will receive placebo. This trial has 2 parts. The purpose of the first part is to find out if acasunlimab at various doses is safe and to find out the best doses of acasunlimab to use. The purpose of the second part is to give acasunlimab to more subjects to see how well the doses of acasunlimab selected in the first part work against cancer when given alone and how well they work when given with pembrolizumab with or without chemotherapy. Trial details include: * The average trial duration for an individual subject will be about 74 weeks. * The average treatment duration for an individual subject will be about 21 weeks. * The visit frequency will be weekly at first and lessening over time until visits are only once every 3 weeks.

Conditions

  • Solid Tumors

Interventions

  • AcasunlimabBiological

    Acasunlimab will be administered intravenously once every 21 days (in selected expansion cohorts acasunlimab will be administered intravenously once every 21 days for the first 2 cycles, and every 42 days in subsequent cycles).

  • Acasunlimab in combination with docetaxel (in a single expansion cohort)Biological

    Acasunlimab and docetaxel will be administered intravenously once every 21 days.

  • Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)Biological

    Acasunlimab and pembrolizumab will be administered intravenously once every 21 days or every 42 days, respectively.

  • Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts)Biological

    Acasunlimab and pembrolizumab and standard chemotherapy will be administered intravenously once every 21 days for 4 cycles, followed by treatment with acasunlimab and pembrolizumab once every 21 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation: Number of Participants With Dose Limiting Toxicities (DLT)Time frame: During first cycle (21 days)
  2. Dose Escalation and Monotherapy Expansion Cohorts: Number of Participants With Treatment-emergent Adverse Events (AEs)Time frame: Up to approximately 5 years, 10 months
  3. Expansion Cohort 1: Objective Response Rate (ORR)Time frame: Up to approximately 5 years, 10 months

Locations

57 sites in 10 countries. Site status is shown where the registry gives one.

  • Mayo Clinic

    Phoenix, Arizona

  • Yale University Cancer Center

    New Haven, Connecticut

  • Mayo Clinic

    Jacksonville, Florida

  • Emory University

    Atlanta, Georgia

  • University of Iowa Hospitals

    Iowa City, Iowa

  • Norton Healthcare Inc

    Louisville, Kentucky

  • University of Michigan

    Ann Arbor, Michigan

  • START Midwest

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University School of Medicine

    St Louis, Missouri

  • NYU Langone

    New York, New York

  • UNC Chapel Hill

    Chapel Hill, North Carolina

  • Levine Cancer Institute, Atrium Health

    Charlotte, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Fakultni nemocnice Brno

    Brno, Czechia

  • University Hospital Brno

    Brno, Czechia

  • Nemocnice AGEL Ostrava-Vítkovice a.s.

    Nový Jičín, Czechia

  • Fakultni nemocnice Olomouc

    Olomouc, Czechia

  • High Technology Hospital Medcenter

    Batumi, Georgia

  • LLC "TIM - Tbilisi Institute of Medicine"

    Tbilisi, Georgia

  • LTD Consilium Medulla

    Tbilisi, Georgia

  • Tbilisi State Medical University and Ingorovka High Medical Technology University Clinic Ltd

    Tbilisi, Georgia

  • Onkologiai Klinika

    Debrecen, Hungary

  • BKMK Hospital

    Kecskemét, Hungary

  • Pulmonology Hospital Törökbálinti

    Törökbálint, Hungary

  • Rambam Health Care Campus RHCC - Rambam Medical Center

    Haifa, Israel

  • Hadassah Medical Organization HMO - Sharett Institute of Oncology

    Jerusalem, Israel

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, Israel

  • Sheba Medical Center, Ramat Gan

    Tel HaShomer, Israel

  • Policlinico San'Orsola

    Bologna, Italy

  • IRCCS - Istituto Europeo di Oncologia IEO

    Milan, Italy

  • Istituto Nazionale Tumori - Fondazione Pascale Italy

    Naples, Italy

  • Azienda Ospedaliero Universitaria di Parma

    Parma, Italy

  • AUSL Romagno-Ravenna

    Ravenna, Italy

  • Policlinico Uni. Campus Bio-Medico

    Roma, Italy

  • Regina Elena National Cancer Institute

    Rome, Italy

  • ASST Sette Laghi "Ospedale di Circolo e Fondazione Macchi "

    Varese, Italy

  • Uniwersyteckie Centrum Kliniczne

    Gdansk, Poland

  • Medpolonia Sp. z o.o.

    Poznan, Poland

  • Specialist Hospital in Prabuty

    Prabuty, Poland

Showing 40 of 57 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.